Contrasting of Infinity Pharmaceuticals Inc. (INFI) and Adverum Biotechnologies Inc. (NASDAQ:ADVM)

Both Infinity Pharmaceuticals Inc. (NASDAQ:INFI) and Adverum Biotechnologies Inc. (NASDAQ:ADVM) are Biotechnology companies, competing one another. We will contrast their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Infinity Pharmaceuticals Inc. 22.00M 3.28 10.33M 1.25 1.01
Adverum Biotechnologies Inc. 2.00M 110.48 71.76M -1.04 0.00

In table 1 we can see Infinity Pharmaceuticals Inc. and Adverum Biotechnologies Inc.’s top-line revenue, earnings per share and valuation.


Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Infinity Pharmaceuticals Inc. -46.95% -20.8% -18.2%
Adverum Biotechnologies Inc. -3,588.00% -32.7% -30.8%

Risk & Volatility

Infinity Pharmaceuticals Inc. is 156.00% more volatile than S&P 500 because the company has a beta of 2.56. Competitively, Adverum Biotechnologies Inc. is 272.00% more volatile than S&P 500, because of the 3.72 beta.


The Current Ratio and Quick Ratio of Infinity Pharmaceuticals Inc. are 10.7 and 10.7 respectively. Its competitor Adverum Biotechnologies Inc.’s Current Ratio is 22.1 and its Quick Ratio is 22.1. Adverum Biotechnologies Inc. can pay off short and long-term obligations better than Infinity Pharmaceuticals Inc.

Analyst Recommendations

The Ratings and Recommendations for Infinity Pharmaceuticals Inc. and Adverum Biotechnologies Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Infinity Pharmaceuticals Inc. 1 1 1 2.33
Adverum Biotechnologies Inc. 0 0 0 0.00

The consensus target price of Infinity Pharmaceuticals Inc. is $3, with potential upside of 136.22%.

Institutional & Insider Ownership

Roughly 53.1% of Infinity Pharmaceuticals Inc. shares are owned by institutional investors while 70.1% of Adverum Biotechnologies Inc. are owned by institutional investors. 1.5% are Infinity Pharmaceuticals Inc.’s share owned by insiders. Competitively, insiders own roughly 1.2% of Adverum Biotechnologies Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Infinity Pharmaceuticals Inc. -5.26% -49.4% -42.2% -31.89% -36.36% -37.93%
Adverum Biotechnologies Inc. 2.51% -0.27% -45.07% -40.65% 13.23% 5.14%

For the past year Infinity Pharmaceuticals Inc. had bearish trend while Adverum Biotechnologies Inc. had bullish trend.


Infinity Pharmaceuticals Inc. beats Adverum Biotechnologies Inc. on 9 of the 12 factors.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Its lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma) is in Phase 1 clinical study. The company has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has a pipeline that includes product candidates to treat wet age-related macular degeneration (wAMD), alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. Its lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT. The company is also developing ADVM-053 to treat hereditary angioedema; and other product candidates, such as ocular therapeutics, including AVA-311 for the treatment of juvenile X-linked retinoschisis. It has collaboration agreements with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products for ophthalmic diseases; and Editas Medicine, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.